10-Q: America Great Health Reports Increased Sales but Continues to Face Going Concern Challenges in Q3 2025

America Great Health's Q3 2025 report shows increased sales due to new product launches, but the company still faces substantial doubt about its ability to continue as a going concern due to recurring net losses and a significant shareholders' deficit.

Summary

• America Great Health's Q3 2025 report reveals increased sales compared to the same period in 2024, primarily driven by the introduction of new products.
• Sales for the nine months ended March 31, 2025, reached $287,213, up from $199,019 in 2024.
• The cost of goods sold also increased to $25,508 from $20,623, correlating with the new product launches.
• Despite the increased sales, the company reported a net loss of $499,046 for the nine months ended March 31, 2025, which is an improvement compared to the $634,833 loss in 2024.
• The company's auditors have raised concerns about its ability to continue as a going concern, citing recurring net losses and a shareholders' deficit of $5,709,609 as of March 31, 2025.
• The company's ability to continue as a going concern is dependent on securing additional sources of capital and the success of the company's plan.
• The company had a cash balance of $36,880 as of March 31, 2025.
• The company intends to finance operating costs over the next twelve months with existing cash on hand and advances from the current majority shareholder.
• The company is raising additional capital to achieve profitable operations.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the increased sales being overshadowed by the going concern warning, significant shareholders' deficit, and ineffective internal controls.

Positives

• Sales increased to $287,213 for the nine months ended March 31, 2025, compared to $199,019 for the same period in 2024, driven by new product launches.
• The net loss decreased to $499,046 for the nine months ended March 31, 2025, from $634,833 in 2024.

Negatives

• The company has a shareholders' deficit of $5,709,609 as of March 31, 2025.
• The company's cash balance was $36,880 as of March 31, 2025.
• The company's auditors have raised concerns about its ability to continue as a going concern.
• The company has negative working capital of $3,512,342 as of March 31, 2025.

Risks

• The company's ability to continue as a going concern is under substantial doubt due to recurring net losses and a significant shareholders' deficit.
• The company's cash balance is low, and it is relying on advances from the majority shareholder to finance operations.
• The company's disclosure controls and procedures are not effective.
• The company lacks a functioning audit committee, independent directors, and an effective review process, which could lead to material misstatements in financial statements.
• The company has significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting.

Future Outlook

The company's future operations depend on its ability to achieve profitable operations and raise the necessary capital to pay ongoing expenses.

Management Comments

• Management believes that the material weaknesses set forth in above did not have an effect on our financial results.
• Management believes that the lack of a functioning audit committee and the lack of a majority of outside directors on our board of directors results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods.

Industry Context

The company operates in the healthcare ecosystem, focusing on innovative technologies, protein and peptide small molecular drugs research and development, diagnostic and medical devices with AI cloud computing, cell therapy and regenerational medicine and supplements manufacturing and sales.

Comparison to Industry Standards

• It is difficult to compare America Great Health's results to industry standards due to its unique business model and focus on innovative technologies within the healthcare sector.
• The company's financial performance should be benchmarked against similar-sized companies in the biotechnology and healthcare sectors, considering factors such as revenue growth, profitability, and cash flow.
• Given the company's focus on research and development, it would be useful to compare its R&D spending and pipeline progress to those of comparable companies in the pharmaceutical and biotechnology industries.

Related Party Transactions

• During the nine months ended March 31, 2025, the Company's current majority shareholder advanced $136,527 to the Company as working capital and the Company repaid $178,638 to the shareholder.
• As of March 31, 2025 and June 30, 2024, the Company owed its current majority shareholder $1,068,085 and $1,110,196, respectively.
• The advances are non-interest bearing and are due on demand.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern issues and potential dilution from future capital raises.
• Employees' job security is uncertain due to the company's financial instability.
• Customers and suppliers may be concerned about the company's ability to fulfill its obligations.

Next Steps

• The company needs to secure additional sources of capital to continue as a going concern.
• The company needs to improve its internal controls and procedures to ensure accurate financial reporting.
• The company needs to achieve profitable operations to improve its financial position.

Key Dates

Keywords

financial results, going concern, net loss, sales increase, shareholders deficit, America Great Health, financial statements, Q3 2025